Gilteritinib (Xospata®) as monotherapy is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an FLT3 mutation.
|NCPE Assessment Process||Complete|
|Rapid Review commissioned||14/10/2019|
|Rapid Review completed||29/11/2019|
|Rapid Review Outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of gilteritinib compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||02/12/2019|
|Pre-submission consultation with Applicant||03/02/2020|
|Current status||Awaiting HTA submission from Applicant|